AstraZeneca Pharma India Limited has informed the Exchange regarding 'Communication to the shareholders w.r.t. TDS on Dividend'.
ASTRAZEN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
AstraZeneca Pharma India has sent an email communication to its shareholders informing them about the tax deduction at source (TDS) applicable on the dividend recommended by the Board at its May 30, 2025 meeting for FY 2024-25. The communication covers TDS rates and procedures for shareholders whose email addresses are registered with the company or depository participants. A specimen of the communication has been filed with the exchanges and is also available on the company's website. This is an administrative/TDS compliance filing and does not announce any new dividend or change to the previously recommended dividend.
No material impact on shareholders or stock price — this is a routine tax-related communication. Shareholders should review the TDS rates applicable to their category and ensure PAN/email details are updated with the company or their depository to avoid higher tax deduction.